Real-World Data in Post-Trial Access: Turn Access into Evidence

Post-Trial Access (PTA) programs offer more than continued patient care—they represent a powerful opportunity to generate real-world data (RWD) that can shape regulatory, reimbursement, and market access strategies.

In our latest white paper, "Real-World Data in Post-Trial Access: Exploring a Unique Opportunity," Dr. Hasan Kobat explores how PTA programs can:

• Extend data collection beyond clinical trials

• Support long-term efficacy and safety assessments

• Capture patient-reported outcomes to better understand quality of life

• Enhance confidence among regulators and payers

Discover why PTA, when implemented with a robust data framework, is a strategic tool for sponsors—and how Clinigen is uniquely positioned to deliver both patient access and high-quality evidence.

Download the full article now to learn more.